64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Clinical trial NCT04868604 · RECRUITING

Trial details

NCT number: NCT04868604
Sponsor: Clarity Pharmaceuticals Ltd
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Prostatic Neoplasms, Castration-Resistant

Start date: 2021-08-11
Primary completion: 2026-09-01
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.